Occult uterine leiomyosarcoma in women undergoing abdominal and minimally invasive surgeries for myomas
Abstract
Objectives: To estimate (i) the incidence of occult uterine leiomyosarcoma (LMS) in patients operated on for presumedmyomas, and (ii) the proportion of occult LMS to preoperatively diagnosed LMS in a tertiary center.
Material and methods: An Institutional Review Board-approved retrospective cohort study was performed. The electronicdatabase of 30,476 patients was searched for women who had undergone surgery due to presumed myomas (N = 2675) as well as those with uterine LMS recognized via histology (N = 10) between January 2010 and December 2016.
Results: Six of the 2675 treated women had occult LMS (incidence 1:446; 0.002; CI 0.0–0.013), and one underwent power morcellation (incidence 1:951; 0.001; CI 0.0–0.006). Parallel searching revealed that 6 of the 10 cases (60%) with uterine LMS recognized via histology were diagnosed postoperatively, whereas 4 of the 10 (40%) were diagnosed preoperatively. The incidence of LMS morcellation during laparoscopy was 1:951 and, when all MIS cases were included, 1:1178. The patient who underwent LMS morcellation was operated in the general surgery ward 5 years after laparoscopy (omental recurrence).
Conclusions: These results are similar to the first and recent conservative FDA estimations, but two-times lower for
procedures with laparoscopic morcellation and all MIS procedures than for abdominal. Because above half of LMS may be recognized after surgery, the risk of occult LMS and the delay of targeted surgical treatment should be included in all informed consent forms for conservative management of presumed myomas without histology.
Keywords: leiomyosarcomalaparoscopic morcellationmyomectomyhysterectomy
References
- Noorchashm H, Reed A. Tragedy, Trade-offs, and the Demise of Morcellation. New England Journal of Medicine. 2016; 374(26): 2605–2605.
- Goff B. SGO not soft on morcellation: risks and benefits must be weighed. The Lancet Oncology. 2014; 15(4): e148.
- Patient safety must be a priority in all aspects of care. The Lancet Oncology. 2014; 15(2): 123.
- Food and Drug Administration (FDA). SpringerReference. .
- Pritts E, Vanness D, Berek J, et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecological Surgery. 2015; 12(3): 165–177.
- Parker W, Berek J, Pritts E, et al. An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. Journal of Minimally Invasive Gynecology. 2016; 23(3): 303–308.
- Gawron I, Skotniczny K, Ludwin A. Occult uterine malignancy during laparoscopic supracervical hysterectomy. Ginekologia Polska. 2018; 89(9): 467–474.
- Ludwin A, Ludwin I, Pityński K, et al. Transrectal Ultrasound-Guided Hysteroscopic Myomectomy of Submucosal Myomas With a Varying Degree of Myometrial Penetration. Journal of Minimally Invasive Gynecology. 2013; 20(5): 672–685.
- DasGupta A, Cai T, Brown L. Interval Estimation for a Binomial Proportion. Statistical Science. 2001; 16(2): 101–133.
- Daly LE. Confidence Limits Made Easy: Interval Estimation Using a Substitution Method. American Journal of Epidemiology. 1998; 147(8): 783–790.
- Ashby D. Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611. Price: £32.00. Statistics in Medicine. 1991; 10(10): 1635–1636.
- Sheskin D. Handbook of Parametric and Nonparametric Statistical Procedures. Chapman and Hall. 2004.
- Food and Drug Administration (FDA). SpringerReference. .
- Bojahr B, Wilde RDe, Tchartchian G. Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH). Archives of Gynecology and Obstetrics. 2015; 292(3): 665–672.
- Vercellini P, Cribiù F, Bosari S, et al. Prevalence of unexpected leiomyosarcoma at myomectomy: a descriptive study. American Journal of Obstetrics and Gynecology. 2016; 214(2): 292–294.
- Pados G, Tsolakidis D, Theodoulidis V, et al. Prevalence of occult leiomyosarcomas and atypical leiomyomas after laparoscopic morcellation of leiomyomas in reproductive-age women. Human Reproduction. 2017; 32(10): 2036–2041.
- Sizzi O, Rossetti A, Malzoni M, et al. Italian multicenter study on complications of laparoscopic myomectomy. Journal of Minimally Invasive Gynecology. 2007; 14(4): 453–462.
- Brölmann H, Tanos V, Grimbizis G, et al. Options on fibroid morcellation: a literature review. Gynecological Surgery. 2015; 12(1): 3–15.
- Raine-Bennett T, Tucker LY, Zaritsky E, et al. Occult Uterine Sarcoma and Leiomyosarcoma. Obstetrics & Gynecology. 2016; 127(1): 29–39.
- Mahnert N, Morgan D, Campbell D, et al. Unexpected Gynecologic Malignancy Diagnosed After Hysterectomy Performed for Benign Indications. Obstetrics & Gynecology. 2015; 125(2): 397–405.
- Mao J, Pfeifer S, Zheng X, et al. Population-Based Estimates of the Prevalence of Uterine Sarcoma Among Patients With Leiomyomata Undergoing Surgical Treatment. JAMA Surgery. 2015; 150(4): 368.
- Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2016; 95(11): 1228–1234.
- George S, Barysauskas C, Serrano C, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014; 120(20): 3154–3158.
- Gao Z, Li L, Meng Y. A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. PLOS ONE. 2016; 11(2): e0148050.
- Pritts E. The prevalence of occult leiomyosarcoma in women undergoing presumed fibroid surgery and outcomes after morcellation. Current Opinion in Obstetrics and Gynecology. 2017: 1.
- Istre O. Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6 Months With Ulipristal Acetate and Contained Power Morcellation. Journal of Minimally Invasive Gynecology. 2017; 24(2): 198.
